Shanghai Pharmaceuticals
Shanghai Pharmaceuticals Holding Co., Ltd., commonly referred to as Shanghai Pharmaceuticals, is a leading player in the pharmaceutical industry, headquartered in Shanghai, China. Founded in 1994, the company has established a strong presence in both domestic and international markets, focusing on research and development, manufacturing, and distribution of a wide range of pharmaceutical products. With a diverse portfolio that includes prescription drugs, over-the-counter medications, and active pharmaceutical ingredients, Shanghai Pharmaceuticals is recognised for its commitment to quality and innovation. The company has achieved significant milestones, including strategic partnerships and expansions into various therapeutic areas, solidifying its position as a key contributor to global healthcare. Notably, Shanghai Pharmaceuticals has been acknowledged for its robust supply chain and extensive distribution network, enhancing its market competitiveness.
DitchCarbon Score
How does Shanghai Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shanghai Pharmaceuticals's score of 22 is lower than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shanghai Pharmaceuticals's reported carbon emissions
Shanghai Pharmaceuticals, headquartered in CN, currently does not report any specific carbon emissions data, as there are no available figures for kg CO2e emissions. Additionally, the company has not established any documented reduction targets or climate pledges. This lack of data suggests that Shanghai Pharmaceuticals may be in the early stages of developing a comprehensive climate strategy. As of now, there are no emissions inherited from a parent company, and the organisation does not appear to be part of any significant climate initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). Without specific emissions data or reduction commitments, it is challenging to assess the company's climate impact or future commitments in the context of industry standards.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shanghai Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
